Journal Mobile Options
Table of Contents
Vol. 29, No. 3, 2008
Issue release date: September 2008
Tumor Biol 2008;29:195–203

Elevated Expression of UBE2T in Lung Cancer Tumors and Cell Lines

Hao J. · Xu A. · Xie X. · Hao J. · Tian T. · Gao S. · Xiao X. · He D.
aKey Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Beijing Normal University, and bDepartment of Chest Surgery, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The aim of this study was to investigate the association between UBE2T, a member of the ubiquitin-conjugating E2 family, and lung cancer, which has never been reported to date. Therefore, the expression of UBE2T mRNA was examined in normal human tissues and 8 lung cancer cell lines. Subsequently, UBE2T expression was analyzed in 41 lung cancer tissues by PCR and Western blots, as well as in 103 lung cancer specimens by immunohistochemistry. To further elucidate the possible functional role of UBE2T, the protein was overexpressed in NIH3T3 cells. UBE2T mRNA was highly expressed in all lung cancer cell lines examined, while it could not be detected in normal lung tissue. UBE2T was detected in 75.6% of primary lung cancer tissue samples (n = 41) at mRNA level and in 60.9% at protein level. In addition, positive UBE2T staining was observed in 61% of lung cancer specimens (n = 103), particularly in all immunohistochemically stained small cell carcinoma tissues. In normal lung tissue, only weak staining was observed in the basal cells of bronchial epithelium. Overexpression of UBE2T in NIH3T3 cells significantly promoted colony formation in soft agar medium (p < 0.001). In conclusion, UBE2T was significantly upregulated in lung cancer tissue and cell lines, suggesting involvement of UBE2T in the malignant cell phenotype.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin2007;57:43–66.
  2. Osada H, Takahashi T: Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene2002;21:7421–7434.
  3. Rubin DM, Finley D: Proteolysis. The proteasome: a protein-degrading organelle? Curr Biol1995;5:854–858.
  4. Reed SI: Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol 2003;4:855–864.
  5. Aguilar RC, Wendland B: Ubiquitin: not just for proteasomes anymore. Curr Opin Cell Biol 2003;15:184–190.
  6. Sweder K, Madura K: Regulation of repair by the 26S proteasome. J Biomed Biotechnol 2002;2:94–105.
  7. Schmidt M, Hanna J, Elsasser S, Finley D: Proteasome-associated proteins: regulation of a proteolytic machine. Biol Chem 2005;386:725–737.
  8. Shekhar MP, Lyakhovich A, Visscher DW, Heng H, Kondrat N: Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. Cancer Res 2002;62:2115–2124.
  9. McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M: Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 2002;8:1127–1138.
  10. Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A: UbcH10 Is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 2003;63:4167–4173.
  11. Gordon GJ, Appasani K, Parcells JP, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R: Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 2002;23:1017–1024.
  12. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G: Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005;11:5128–5139.
  13. Nanjangud G, Naresh K, Teruya-Feldstein J, Filippa D, Zelenetz A, Chaganti R: Chromosome-change-based gene expression analysis reveals differentially expressed genes/pathways associated with histologic progression and transformation in follicular lymphoma. AACR Meet Abstr 2006, pp 795–796.
  14. Su WH, Chao CC, Yeh SH, Chen DS, Chen PJ, Jou YS: OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res 2007;35:D727–D731.
  15. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059–1068.
  16. Yokota J, Kohno T: Molecular footprints of human lung cancer progression. Cancer Sci 2004;95:197–204.
  17. Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D’Andrea AD, Dutta A: UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell 2006;23:589–596.
  18. Alpi A, Langevin F, Mosedale G, Machida YJ, Dutta A, Patel KJ: UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: a basis for the regulation of FANCD2 monoubiquitination. Mol Cell Biol 2007;27:8421–8430.
  19. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD: E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 2002;16:245–256.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50